Development of serotype-cross-reactive sub-unit vaccines for African horse sickness and bluetongue viruses

Lead Research Organisation: The Pirbright Institute
Department Name: UNLISTED

Abstract

The project will continue and extend previous studies that involved the development of recombinant Modified Vaccinia Ankara (MVA) strains expressing individual proteins of African horse sickness virus (AHSV), to explore their potential as vaccine components for different AHSV serotypes. These studies have previously shown induction of virus neutralizing antibodies in ponies, following vaccination with MVA expressing AHSV-4 VP2. In particular we are interested in understanding the nature of cross-reactive neutralizing-antibody and protective-immune responses. The project primarily involves working with AHSV proteins expressed in MVA, baculovirus and/or bacterial expression systems as potential vaccine components. Initial vaccination efficacy studies will be carried out in a mouse model system, involving collaboration with Javier Ortego at Valdeolmos in Spain.
 
Description BBSRC has indicated that they do not require a response
Exploitation Route BBSRC has indicated that they do not require a response
Sectors Agriculture, Food and Drink

 
Description BBSRC has indicated that they do not require a response
Sector Agriculture, Food and Drink
Impact Types Economic